Evidence map›Paper›PMID 41128344›Full record

ArticleACS chemical biology2025

Development of ArgTag for Scalable Solid-Phase Synthesis of Aggregating Peptides.

Vincent Freiburghaus, Aliénor Jeandin, Łukasz Frankiewicz, Jie Yang, Nina Hartrampf

Abstract read
In one paragraph

Article in ACS chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vincent FreiburghausDepartment of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
Aliénor JeandinDepartment of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.
Łukasz FrankiewiczPeptiSystems AB, Uppsala Business Park, Virdings allé 22, 754 50 Uppsala, Sweden.
Jie YangPeptiSystems AB, Uppsala Business Park, Virdings allé 22, 754 50 Uppsala, Sweden.
Nina HartrampfDepartment of Chemistry, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland.ORCID 0000-0003-0875-6390

Funding

Swiss National Science Foundation 200021_200865
6 · The paper itself

Abstract

Aggregation during solid-phase peptide synthesis (SPPS) remains a key limitation, often leading to low coupling efficiencies and poor crude purities. Our previously introduced synthesis tag ("SynTag") for chemical protein synthesis combines six C-terminal Arg(Pbf) residues with a MeDbz linker to suppress aggregation via helical structure induction and serves as a handle for native chemical ligation (NCL). To apply the concept to short, yet aggregation-prone sequences, some practical limitations need to be addressed: Tag removal needs to be simplified, its utility demonstrated on more commonly used resin types and loadings, and the method must be effective on larger scale. To this end, we developed a simplified C-terminal hexaarginine tag ("ArgTag") and refined an enzymatic method for efficient removal with Carboxypeptidase B, enabling selective cleavage under mild, linker-free conditions. We evaluated the ArgTag across six solid supports (resins) of varying polarity and loading. Using automated fast-flow SPPS (AFPS), we observed consistent aggregation suppression and improved crude purities across all resin types. We finally demonstrated the efficiency of our ArgTag on larger scale using more economical synthesis parameters. This work broadens the applicability of the SynTag strategy to short, yet difficult peptide sequences and offers a more scalable solution to improve SPPS efficiency for challenging targets.

Indexed as

PeptidesSolid-Phase Synthesis TechniquesArginineArgininePeptides

Identifiers

PMID41128344
PMCPMC12645436

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.